Beam Therapeutics Inc.
BEAM
$15.47
$0.845.74%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 110.72% | 21.21% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 110.72% | 21.21% | |||
| Cost of Revenue | 7.62% | 8.29% | |||
| Gross Profit | 10.77% | -6.27% | |||
| SG&A Expenses | 8.09% | -10.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.73% | 3.52% | |||
| Operating Income | 6.07% | -1.53% | |||
| Income Before Tax | 6.53% | -6.21% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 6.53% | -6.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 6.53% | -6.17% | |||
| EBIT | 6.07% | -1.53% | |||
| EBITDA | 6.37% | -1.72% | |||
| EPS Basic | 7.00% | -6.04% | |||
| Normalized Basic EPS | 6.12% | -10.87% | |||
| EPS Diluted | 6.73% | -6.04% | |||
| Normalized Diluted EPS | 6.12% | -10.87% | |||
| Average Basic Shares Outstanding | 0.50% | 0.12% | |||
| Average Diluted Shares Outstanding | 0.50% | 0.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
